Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Do atypical antipsychotics cause stroke?

Nathan Herrmann1, Krista L Lanctôt

  • 1Division of Geriatric Psychiatry, University of Toronto, Toronto, Ontario, Canada. nathan.hermann@sw.ca

CNS Drugs
|February 9, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Amygdala and hippocampal volumes as neural correlates of resilience and loneliness in older adults.

Neurobiology of aging·2026
Same author

Simulation of long-term lecanemab treatment effect on Alzheimer's disease progression.

Alzheimer's & dementia (New York, N. Y.)·2026
Same author

Angiogenesis markers and cognitive response in a randomized trial of cognitive remediation plus transcranial direct current stimulation in older adults at risk of dementia.

Journal of Alzheimer's disease : JAD·2026
Same author

Brain Structures and Cognitive Decline: Moderation Analysis of the PACt-MD Randomized Clinical Trial of Brain Stimulation Plus Cognitive Remediation in Older Adults With Remitted Depression or Mild Cognitive Impairment.

The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry·2026
Same author

Synaptic biomarkers in Alzheimer's disease dementia and mild cognitive impairment: A systematic review and meta-analysis.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same author

Uncovering lipid biomarkers linked to methylphenidate efficacy in treating apathy in Alzheimer's disease: insights from the ADMET 2 trial.

Alzheimer's research & therapy·2026
Same journal

Impact of Omaveloxolone on Serum Lipids in Patients with Friedreich Ataxia: A 1-Year Real-World Analysis.

CNS drugs·2026
Same journal

Emerging Pharmacological Strategies for Trigeminal Neuralgia.

CNS drugs·2026
Same journal

Psychiatric Symptoms Associated with Corticosteroid Use: A Systematic Review and Meta-analysis.

CNS drugs·2026
Same journal

Anti-CD20 Therapies in Pediatric Acquired Demyelinating Syndromes: Evidence Across MS, AQP4-IgG-Positive NMOSD and MOGAD.

CNS drugs·2026
Same journal

Isoform-Specific NaV Modulation in Painful Chemotherapy-Induced Neuropathy: Promise, Limitations, and a Clinical Agenda.

CNS drugs·2026
Same journal

Correction: Seletracetam Revisited: A Missed Opportunity for Effective Epilepsy Therapy.

CNS drugs·2026
See all related articles

Elderly dementia patients taking risperidone or olanzapine showed more cerebrovascular events than placebo. However, large studies suggest these antipsychotics do not increase stroke risk compared to other treatments.

Area of Science:

  • Geriatric Medicine
  • Neuroscience
  • Pharmacology

Background:

  • Atypical antipsychotics like risperidone and olanzapine are used for behavioral disturbances in elderly dementia patients.
  • Concerns exist regarding cerebrovascular adverse events (CVAEs) associated with these medications.

Purpose of the Study:

  • To analyze the incidence of CVAEs in elderly dementia patients treated with risperidone and olanzapine.
  • To compare the risks of CVAEs between atypical antipsychotics, placebo, and other treatments for dementia.

Main Methods:

  • Post hoc analysis of pooled data from 11 randomized controlled trials (RCTs) of risperidone and olanzapine.
  • Reanalysis of risperidone trials to differentiate strokes from non-specific events.
  • Review of large observational health database studies.

Related Experiment Videos

Main Results:

  • Pooled RCTs showed increased CVAEs with risperidone and olanzapine versus placebo.
  • Reanalysis suggested some reported CVAEs were not strokes.
  • Observational studies indicated no increased stroke risk for risperidone/olanzapine compared to typical antipsychotics or untreated patients.
  • Higher incidence of CVAEs in risperidone trials likely due to more vascular dementia patients included.

Conclusions:

  • The association between atypical antipsychotics and CVAEs in elderly dementia patients requires further investigation.
  • While some CVAEs were observed in trials, large database studies do not consistently support an increased stroke risk.
  • Clinicians must weigh the risks and benefits of atypical antipsychotics for behavioral disturbances in this population.